Expert Interview
Digging into Gilead's Trodelvy (sacituzimab govitecan-hziy) after FDA approval in pre-treated HR+/HER2- metastatic breast cancer
Ticker(s): GILDInstitution: StonyBrook Cancer Center
- Chief, Division of Hematology/Oncology and Associate Director of Clinical and Translational Research at Stony Brook Cancer Center.
- Manages approximately 10 patients with HR+/HER2- mBC.
- Clinical research in breast cancer include biomarker discovery including the use of functional imaging for predicting breast cancer risk and response to antitumor therapies and role of non-steroidal anti-inflammatory drugs (NSAIDs) in breast cancer prevention.
Roughly how many patients do you manage with HR+/HER2- mBC
Added By: dami_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for trodelvy ?
Added By: dami_adminPlease describe your practice as a clinician,how many patients with HR+/HER2- Metastatic Breast Cancer do you see on a yearly basis? Can you describe the standard of care, and take us through the most promising upcoming treatments?
How much of an unmet need is there for HR+/HER2- Metastatic Breast Cancer? How competitive and effective is Endocrine therapy or Chemotherapy?
Could you walk us through the details regarding Trodelvy’s mechanism of action and composition, and how that translate into beneficial patient outcomes:- Monoclonal antibody: The humanized monoclonal antibody, hRS7 IgG1κ, that binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers, including triple-negative breast cancer (TNBC)- Cytotoxic drug: The camptothecin-derived agent, SN-38, a topoisomerase I inhibitor act by interfering with the replicative capacity of cancer cells.-Linker: A hydrolyzable linker, with a short PEGylated unit.
How do Trodelvy, Trastuzumab emtansine (Kadcyla) and Trastuzumab deruxtecan (Enhertu) compare to eachother?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
